Neuro-Ophthalmic Literature Review

Abstract

Greater attenuation of retinal atrophy may occur after 12 months of rituximab treatment, following which time GCIPL atrophy rates are similar to those observed among natalizumab-treated patients with RRMS and HCs. I Xiaojun Zhang i Visuomotor performance as the proxy of training-related function recovery in patients with mu... Lipp I, Foster C, Stickland R, Sgarlata E, Tallantyre EC, Davidson AE, Robertson NP, Jones DK, Wise RG, Tomassini V. Predictors of training-related improvement in visuomotor performance in patients with multiple sclerosis: A behavioural and MRI study. I Michael S. Vaphiades i Modulation of retinal atrophy with rituximab in multiple sclerosis Lambe J, Risher H, Filippatou AG, Murphy OC, Sotirchos ES, Ehrhardt H, Ogbuokiri E, Pellegrini N, Toliver B, Luciano NJ, Davis S, Fioravante N, Kwakyi O, Prince JL, Calabresi PA, Fitzgerald KC, Saidha S. Modulation of Retinal Atrophy With Rituximab in Multiple Sclerosis. This study conducted by a British multidisciplinary group of researchers chose visuo-motor performance as the proxy of functional recovery of multiple sclerosis (MS) patients after undergoing a 4-weeks homebased training session, combing demographic with baseline clinical features and magnetic resonance imaging (MRI) measures to predict function recovery of MS patients. [Extracted from the article] Copyright of Neuro-Ophthalmology is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)